Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427021 · ClinicalTrials.gov registry record · Early Phase 1
A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 65
- Enrollment target
NCT03427021 is a Early Phase 1 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 65 participants.
The verdict
NCT03427021, a Early Phase 1 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate whether exposure to ice chips in the mouth (oral ice chips) during oxaliplatin treatment prevents or reduces symptoms of cold sensitivity.
Interventions
- DRUG Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-10-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03427021
The ClinicalTrials.gov registry entry for NCT03427021 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxaliplatin is the first listed.
NCT03427021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03427021 about?
NCT03427021 is a clinical study titled "A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity". The main purpose of this study is to evaluate whether exposure to ice chips in the mouth (oral ice chips) during oxaliplatin treatment prevents or reduces symptoms of cold sensitivity.
What is the current status of trial NCT03427021?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 65 participants. The study started on 2017-02-01. Estimated completion is 2018-10-23.
What interventions are being tested in trial NCT03427021?
The interventions under investigation include: Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT03427021?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.